公开(公告)号：US20250049814A1

公开(公告)日：2025-02-13

申请号：US18925841

申请日：2024-10-24

Applicant: MERCK PATENT GMBH

Inventor： Anne-Laure BLAYO ,  Baptiste MANTEAU ,  Camille AMALRIC ,  Stanislas MAYER ,  Stephan SCHANN ,  Mickaël FER

IPC: A61K31/553 ,  A61K31/4545 ,  A61K31/46 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5386 ,  A61P35/00 ,  C07D471/04 ,  C07D519/00

Abstract: The present invention relates to novel 5-azaindazole derivatives of formula (I), as described and defined herein, and pharmaceutically acceptable salts, solvates and prodrug thereof, as well as pharmaceutical compositions comprising such compounds. The 5-azaindazole derivatives according to the invention have been found to be highly effective dual A2A/A2B adenosine receptor antagonists, and can thus be used as therapeutic agents, particularly in the treatment or prevention of hyperproliferative or infectious diseases or disorders.

公开(公告)号：US12171764B2

公开(公告)日：2024-12-24

申请号：US17253807

申请日：2019-06-19

Applicant: BIORA THERAPEUTICS, INC.

Inventor： Mitchell Lawrence Jones ,  Sharat Singh ,  Christopher Loren Wahl ,  Harry Stylli ,  Kevin David Howe ,  Arana Perera

IPC: A61K31/519 ,  A61K9/00 ,  A61K31/4196 ,  A61K31/437 ,  A61K31/46 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61P1/00

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a JAK or other kinase inhibitor.

公开(公告)号：US12161585B2

公开(公告)日：2024-12-10

申请号：US17119905

申请日：2020-12-11

Applicant: Eyenovia, Inc.

Inventor： Luke W. Clauson ,  Rex Dwyer ,  Matthew Newell ,  Michael Owens

IPC: A61F9/00 ,  A61K31/135 ,  A61K31/222 ,  A61K31/4164 ,  A61K31/4409 ,  A61K31/46 ,  A61K47/02 ,  A61K47/18

Abstract: A device for delivering a volume of fluid to an eye including a base having a drive mechanism and a disposable fluid cartridge configured to releasably couple to the base to form the device. Related systems, devices, compositions, and methods of use are provided.

公开(公告)号：US12102628B2

公开(公告)日：2024-10-01

申请号：US17706225

申请日：2022-03-28

Applicant: Seinda Pharmaceutical Guangzhou Corporation

Inventor： Hui Ouyang ,  Yong Qiu

IPC: A61P27/02 ,  A61K9/00 ,  A61K31/06 ,  A61K31/216 ,  A61K31/222 ,  A61K31/24 ,  A61K31/4168 ,  A61K31/417 ,  A61K31/439 ,  A61K31/4406 ,  A61K31/46 ,  A61K31/498 ,  A61K31/551 ,  A61K31/5513 ,  A61P27/10 ,  C07C217/20 ,  C07C219/10 ,  C07D213/04 ,  C07D235/02 ,  C07D403/04 ,  C07D403/12 ,  C07D471/08 ,  C07D487/04 ,  C07D491/18

CPC classification number: A61K31/46 ,  A61K9/0048 ,  A61K31/24 ,  A61K31/4168 ,  A61K31/417 ,  A61K31/498 ,  A61K31/551 ,  A61P27/10

Abstract: Compositions and methods useful in slowing, inhibiting, or regressing the progression of myopia, while minimizing pupil dilation and light sensitivity are provided herein. Provided compositions can include a muscarinic receptor antagonist and a miotic agent.

公开(公告)号：US20240307334A1

公开(公告)日：2024-09-19

申请号：US18407998

申请日：2024-01-09

Applicant: Lieber Institute, Inc. ,  Oregon Health & Science University

Inventor： Brady Maher ,  Joseph Bohlen ,  Thomas Scanlan

IPC: A61K31/192 ,  A61K31/137 ,  A61K31/165 ,  A61K31/216 ,  A61K31/222 ,  A61K31/40 ,  A61K31/4025 ,  A61K31/439 ,  A61K31/445 ,  A61K31/4453 ,  A61K31/46 ,  A61K31/5386 ,  A61P25/28

CPC classification number: A61K31/192 ,  A61K31/137 ,  A61K31/165 ,  A61K31/216 ,  A61K31/222 ,  A61K31/40 ,  A61K31/4025 ,  A61K31/439 ,  A61K31/445 ,  A61K31/4453 ,  A61K31/46 ,  A61K31/5386 ,  A61P25/28

Abstract: The use of sobetirome or a prodrug or derivative thereof, including Sob-AM2, for treating a disease, disorder, or condition associated with or suspected of being associated with dysmyelination, such as Pitt-Hopkins Syndrome, is disclosed.

公开(公告)号：US12070501B1

公开(公告)日：2024-08-27

申请号：US17976660

申请日：2022-10-28

Applicant: ADS Therapeutics LLC

Inventor： Jinsong Ni ,  Van Dinh ,  Rong Yang

IPC: A01N43/00 ,  A01N43/46 ,  A61K9/00 ,  A61K31/46 ,  A61K31/55 ,  A61K47/06 ,  A61K47/14 ,  A61P27/10

CPC classification number: A61K47/14 ,  A61K9/0048 ,  A61K31/46 ,  A61K47/06 ,  A61P27/10

Abstract: A topical ophthalmological composition includes a muscarinic receptor antagonist as an active pharmaceutical ingredient; and medium chain triglycerides (MCTs) or light liquid paraffin oil as liquid vehicle. The topical ophthalmological composition treats an ocular disease.

公开(公告)号：US20240269133A1

公开(公告)日：2024-08-15

申请号：US18561405

申请日：2022-05-20

Applicant: Purdue Pharma L.P.

Inventor： Garth WHITESIDE ,  Stephen HARRIS

IPC: A61K31/498 ,  A61K31/137 ,  A61K31/216 ,  A61K31/4025 ,  A61K31/46 ,  A61K31/4725 ,  A61P13/10

CPC classification number: A61K31/498 ,  A61K31/137 ,  A61K31/216 ,  A61K31/4025 ,  A61K31/46 ,  A61K31/4725 ,  A61P13/10

Abstract: The disclosure provides a method of treating interstitial cystitis/bladder pain syndrome in a human subject in need of such treatment, comprising administering to the human subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In certain embodiments, the method comprises administering the compound of formula (IA).

公开(公告)号：US20240262832A1

公开(公告)日：2024-08-08

申请号：US18288928

申请日：2022-04-28

Applicant: Vanqua Bio, Inc.

Inventor： Kevin Hunt ,  Jianbin Zheng ,  Sida Shen

IPC: C07D487/04 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/46 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  C07D211/52 ,  C07D401/04 ,  C07D401/06 ,  C07D401/14 ,  C07D405/06 ,  C07D405/14 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/06 ,  C07D417/14 ,  C07D471/04

CPC classification number: C07D487/04 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/46 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  C07D211/52 ,  C07D401/04 ,  C07D401/06 ,  C07D401/14 ,  C07D405/06 ,  C07D405/14 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/06 ,  C07D417/14 ,  C07D471/04

Abstract: Provided herein are compounds that modulate glucocerebrosidase (GCase), an enzyme whose activity is associated with neurological diseases and disorders (e.g., Gaucher's disease. Parkinson's disease). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating GCase-related diseases and disorders (e.g., Gaucher's disease. Parkinson's disease) with the compounds in a subject, by administering the compounds and/or compositions described herein.

公开(公告)号：US20240226004A1

公开(公告)日：2024-07-11

申请号：US18606272

申请日：2024-03-15

Applicant: KINDEVA DRUG DELIVERY L.P.

Inventor： Philip A. JINKS

IPC: A61K9/00 ,  A61K31/46 ,  A61K47/06

CPC classification number: A61K9/008 ,  A61K31/46 ,  A61K47/06

Abstract: Stable composition of anhydrous micronized ipratropium or a pharmaceutically acceptable anhydrous salt thereof and method of making.

公开(公告)号：US20240207279A1

公开(公告)日：2024-06-27

申请号：US18420659

申请日：2024-01-23

Applicant: Cardix Therapeutics LLC

Inventor： Jin Jean Wang ,  Gerald J. Yakatan ,  Ting N. Lin ,  Jing H. Gao

IPC: A61K31/522 ,  A61K31/137 ,  A61K31/4402 ,  A61K31/4422 ,  A61K31/455 ,  A61K31/46 ,  A61K31/575 ,  A61P9/06

CPC classification number: A61K31/522 ,  A61K31/137 ,  A61K31/4402 ,  A61K31/4422 ,  A61K31/455 ,  A61K31/46 ,  A61K31/575 ,  A61P9/06

Abstract: Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist. Also provided herein is a method of treating, preventing, or ameliorating a cardiovascular disease in a subject, comprising administering to the subject in need thereof two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist.